Vetter plans to invest $320 million on 10-year expansion plan
Company provides insights into its long-term expansion plans that include the purchasing of property in the City of Des Plaines
At a meeting held on 12 July for interested residents and other stakeholders, officials of the City of Des Plaines and Vetter were given the opportunity to share initial plans for the proposed purchase and development by Vetter of a 18-acre site, located at the corner of Mount Prospect and Algonquin Road. Vetter's initial concept intends to offer its global customer base a US manufacturing opportunity for their market supply needs of commercialised drugs.
Vetter provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of injectable drugs. For this project, the company plans investments of approximately $320 million on construction and site improvements over more than 10 years. Once it has reached its final expansion stage, the 18-acre site would include 1,138,237 sq. ft. of facility space. If approved, the facility would be the second US manufacturing site of the company. The Des Plaines project would complement its existing US clinical development support service offering which consists of a small-scale manufacturing facility located in the nearby Village of Skokie. Des Plaines would be the recipient of several positive outcomes including the creation of approximately 400–500 new jobs by the final expansion stage. Many of these are expected to be hired locally.
“We believe that this project represents a win-win scenario for the residents of Des Plaines and Vetter alike,” said Vetter Managing Director Peter Soelkner. “For us, it would be the next step in our plan for continuous growth. Several of our customers have requested commercial manufacturing resources both in US and Europe for their multi-facetted market production needs. Being in a continuous dialogue with them, such a facility would enlarge Vetter’s geographical manufacturing opportunities, and thus, increase our customer’s flexibility. We are excited about the positive outcomes this project can bring to the city of Des Plaines, and becoming a good and trustworthy neighbour to its residents. Des Plaines is a great partner in the process, we would be happy to receive the projects approval,” said Soelkner.
Founded as a modest pharmacy in Ravensburg, Germany, the company has grown from a local packager to a world-leading contract development and manufacturing organisation, today serving the top 10 (bio-)pharmaceutical companies as well as small and midsize companies. If approved and realised, the facility would complement Vetter’s existing site at the Illinois Science+Technology Park in Skokie which has approximately 70 employees, most of whom are local residents. The purpose and scope of work between the two facilities would not be overlapping, but acting as a complementary service to its customers.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance